News
RGEN
157.14
+0.05%
0.08
Positive Report for Repligen (RGEN) from Craig-Hallum
TipRanks · 20h ago
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Repligen Corporation (NASDAQ:RGEN) does carry debt. At the end of December 2023, Repligen had US$579.6m of debt. Its balance sheet shows it holds US$751.3m in cash. The company has more cash than debt and a decent-looking balance sheet. Repligen has two warning signs we think you should be aware of. It's worth looking at Repligen's free cash flow to see if the debt is a concern.
Simply Wall St · 4d ago
Weekly Report: what happened at RGEN last week (0408-0412)?
Weekly Report · 5d ago
908 Devices: Rare Early-Stage Bioprocess Investment Opportunity
908 Devices, Inc. Is a company focused on mass spectrometry and bioprocessing 4.0. The company has three main platforms for growth in the forensic industry. Life science tools are essential for the growth of the healthcare industry. 908 Devices is a rare early-stage investment opportunity in the life science tools industry.
Seeking Alpha · 04/10 16:49
RBC Capital Remains a Buy on Repligen (RGEN)
Repligen Corp. Provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The company’s shares closed yesterday at $174.05. The analyst consensus on Repligen is a Strong Buy with an average price target of $216.00.
TipRanks · 04/09 01:45
Weekly Report: what happened at RGEN last week (0401-0405)?
Weekly Report · 04/08 09:10
REPLIGEN CORP <RGEN.O>: RBC CUTS TARGET PRICE TO $221 FROM $225
Reuters · 04/08 06:30
Relative Strength Alert For Repligen
NASDAQ · 04/02 16:18
Weekly Report: what happened at RGEN last week (0325-0329)?
Weekly Report · 04/01 09:10
Should Weakness in Repligen Corporation's (NASDAQ:RGEN) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Repligen (NASDAQ:RGEN) has a return on equity of 2.1%. The company grew its net income at a rate of 34% in the last five years. Repligen's ROE is lower than the average for its industry. The company has a good growth rate, but is not considered a good indicator of future growth. It has a better ROE than the industry average of 12%. Repligen is currently down 7.9% for the week.
Simply Wall St · 03/29 14:48
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Shares of Aehr Test System tumbled 18.1% to $12.01 on Monday. The company reported preliminary third-quarter and FY24 results below estimates. The Dow Jones index fell around 100 points in today's session. Vimeo, Canopy Growth Corporation and United Airlines also recorded losses.
Benzinga · 03/25 14:32
Weekly Report: what happened at RGEN last week (0318-0322)?
Weekly Report · 03/25 09:10
Repligen: Current report
Press release · 03/19 12:52
Repligen Corp Announces Board Appointment and Compensation Plan
TipRanks · 03/19 11:52
Press Release: Repligen Appoints Maggie A. Pax to Board of Directors
Repligen Appoints Maggie A. Pax to Board of Directors. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. Pax served as Vice President, Strategy and Innovation at Thermo Fisher Scientific for eight years. Ms. Pax's appointment expands Repligen's board from eight to nine.
Dow Jones · 03/19 11:30
Weekly Report: what happened at RGEN last week (0311-0315)?
Weekly Report · 03/18 09:10
This Insider Has Just Sold Shares In Repligen
Anthony Hunt, the CEO & Director of Repligen Corporation recently sold shares for US$3.3m. This is the biggest insider sale of the company in the last year. In total, Repligen insiders sold more than they bought over the last decade. Insiders own 0.6% of repligen Corporation. We found two warning signs for Repligen that deserve your attention. Repligen has been selling shares at around the current price.
Simply Wall St · 03/14 13:01
Weekly Report: what happened at RGEN last week (0304-0308)?
Weekly Report · 03/11 09:10
Weekly Report: what happened at RGEN last week (0226-0301)?
Weekly Report · 03/04 09:10
Chief Operating Officer Of Repligen Sold 100% Of Their Shares
James Bylund, the Chief Operating Officer of Repligen Corporation, sold US$680k worth of shares recently. The insider sale is the biggest in the last year at Repligen. In the last 12 months, an insider has sold more shares in Repligen than they bought in the company. Repligen owns 0.5% of the Company. It's important to check how many shares Repligen shares are held by an insider.
Simply Wall St · 02/29 12:51
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.